MCID: OPT003
MIFTS: 55

Opiate Dependence

Categories: Mental diseases

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence 12 15
Opioid Dependence 76 55
Opioid-Related Disorders 73
Opioid Type Dependence 12
Opiate Addiction 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2559
ICD10 33 F11.2
ICD9CM 35 304.0 304.00
MeSH 44 D009293
SNOMED-CT 68 75544000

Summaries for Opiate Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid dependence, is related to opioid dependence 1 and opioid addiction. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Buprenorphine and Naloxone have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Opioid use disorder is a problematic pattern of opioid use that causes significant impairment or... more...

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Related Disease Score Top Affiliating Genes
1 opioid dependence 1 33.8 ODS1 OPRM1
2 opioid addiction 31.5 DRD2 OPRD1 OPRK1 OPRM1
3 morphine dependence 31.4 CREB1 OPRD1 OPRK1 OPRM1
4 heroin dependence 31.1 DRD2 OPRD1 OPRM1 PDYN
5 psychotic disorder 30.4 DRD2 DRD3 SLC6A4 TPH1
6 substance abuse 30.1 DRD2 DRD3 SLC6A4
7 personality disorder 30.0 DRD2 SLC6A4 TPH1
8 conduct disorder 30.0 DRD2 SLC6A4 TPH1
9 panic disorder 29.9 POMC SLC6A4 TPH1
10 withdrawal disorder 29.9 OPRM1 PDYN POMC
11 neonatal abstinence syndrome 29.8 OPRD1 OPRK1 OPRM1
12 alcohol abuse 29.8 DRD2 DRD3 SLC6A4
13 schizoaffective disorder 29.7 DRD2 DRD3 SLC6A4
14 schizophrenia 29.6 DRD2 DRD3 SLC6A4 TH TPH1
15 attention deficit-hyperactivity disorder 29.6 DRD2 DRD3 OPRM1 SLC6A4 TH TPH1
16 restless legs syndrome 29.5 DRD2 DRD3 POMC TH
17 pain agnosia 29.1 OPRK1 OPRM1 PDYN POMC
18 bipolar disorder 29.1 CREB1 DRD2 DRD3 IGF1 SLC6A4 TH
19 disease of mental health 29.0 DRD2 DRD3 OPRM1 PDYN POMC SLC6A4
20 alcohol dependence 28.6 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
21 drug dependence 28.4 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
22 gangliocytoma 10.2 POMC TH
23 acidophil adenoma 10.2 IGF1 POMC
24 pituitary infarct 10.2 IGF1 POMC
25 avoidant personality disorder 10.2 SLC6A4 TPH1
26 empty sella syndrome 10.2 IGF1 POMC
27 sick building syndrome 10.2 POMC VEGFA
28 sheehan syndrome 10.2 IGF1 POMC
29 cerebral hypoxia 10.2 CREB1 IGF1
30 alcohol-induced mental disorder 10.1 DRD2 SLC6A4
31 toxic encephalopathy 10.1 CREB1 NGF TH
32 polysubstance abuse 10.1 DRD2 DRD3
33 hyperpituitarism 10.1 IGF1 POMC
34 chronic fatigue syndrome 10.1 IGF1 POMC SLC6A4
35 mental depression 10.1 POMC SLC6A4 TPH1
36 galactorrhea 10.1 DRD2 IGF1
37 anorexia nervosa 10.1 IGF1 POMC SLC6A4
38 endocrine organ benign neoplasm 10.1 IGF1 NGF POMC
39 tardive dyskinesia 10.1 DRD2 DRD3
40 prolactin producing pituitary tumor 10.1 DRD2 NGF
41 pituitary tumors 10.1 IGF1 POMC VEGFA
42 impulse control disorder 10.1 DRD2 DRD3
43 alcoholic psychosis 10.1 DRD2 SLC6A4
44 central nervous system disease 10.1 NGF SLC6A4 TH
45 pathological gambling 10.1 DRD2 DRD3 SLC6A4
46 migraine without aura 10.1 DRD2 DRD3 SLC6A4
47 gonadal disease 10.1 IGF1 POMC VEGFA
48 delusional disorder 10.1 DRD2 DRD3 TH
49 west syndrome 10.1 POMC TH TPH1
50 nervous system disease 10.1 NGF TH VEGFA

Graphical network of the top 20 diseases related to Opiate Dependence:



Diseases related to Opiate Dependence

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 CREB1 DRD2 DRD3 NGF OPRD1 OPRK1
2 homeostasis/metabolism MP:0005376 10.28 CREB1 DRD2 DRD3 IGF1 NGF OPRD1
3 growth/size/body region MP:0005378 10.23 CREB1 DRD2 DRD3 IGF1 NGF OPRM1
4 cardiovascular system MP:0005385 10.21 CREB1 DRD2 DRD3 IGF1 NGF POMC
5 integument MP:0010771 10.18 DRD2 IGF1 NGF OPRD1 OPRK1 OPRM1
6 endocrine/exocrine gland MP:0005379 10.13 CREB1 DRD2 IGF1 OPRK1 OPRM1 POMC
7 adipose tissue MP:0005375 10.08 DRD2 DRD3 IGF1 OPRM1 PDYN POMC
8 mortality/aging MP:0010768 10.07 CREB1 DRD2 DRD3 IGF1 NGF OPRM1
9 nervous system MP:0003631 10.07 CREB1 DRD2 DRD3 IGF1 NGF OPRD1
10 digestive/alimentary MP:0005381 9.97 DRD2 DRD3 OPRK1 OPRM1 PDYN VEGFA
11 muscle MP:0005369 9.87 CREB1 DRD2 IGF1 NGF SLC6A4 TPH1
12 no phenotypic analysis MP:0003012 9.76 DRD2 NGF OPRD1 OPRM1 PDYN POMC
13 normal MP:0002873 9.56 CREB1 DRD2 IGF1 NGF OPRM1 SLC6A4
14 respiratory system MP:0005388 9.1 CREB1 DRD2 IGF1 TH TPH1 VEGFA

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52485-79-7 40400 644073
2
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
3
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 16590-41-3 5360515
4
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
6
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
8
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
9
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
10
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
11
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
12
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
13
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable 54-11-5 942 89594
14
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
15
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
17 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
18
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-42-6 5284603
19
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
20
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2 56-12-2 119
21
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60142-96-3 3446
22
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
23
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
24
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
25
Codeine Approved, Illicit Phase 4 76-57-3 5284371
26
Acetaminophen Approved Phase 4,Not Applicable 103-90-2 1983
27
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
28
Cobicistat Approved Phase 4 1004316-88-4
29
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
30
Heroin Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 561-27-3 5462328
31
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
32 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Analgesics, Opioid Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 490)
# Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4 naloxone;buprenorphine
4 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
5 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
6 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
7 Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
8 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
9 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
10 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
11 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
12 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
13 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
14 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
15 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
16 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
17 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
18 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
19 HIV, Buprenorphine, and the Criminal Justice System (STRIDE2) Completed NCT03583138 Phase 4 buprenorphine
20 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
21 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
22 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
23 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
24 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
25 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
26 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
27 Desvenlafaxine in Opioid-Dependent Patients Completed NCT02200406 Phase 4 Desvenlafaxine
28 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
29 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
30 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
31 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
32 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
33 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
34 Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
35 A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic Recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
36 Houston Emergency Opioid Engagement System Recruiting NCT03396276 Phase 4 Suboxone
37 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
38 Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
39 A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse Recruiting NCT03033732 Phase 4 Methadone;Buprenorphine-Naloxone
40 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
41 Switch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on Methadone Recruiting NCT03549312 Phase 4 Genvoya;Epclusa
42 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
43 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Active, not recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
44 Extended Release Naltrexone for Opioid-Dependent Youth Active, not recruiting NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
45 Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain Active, not recruiting NCT02741076 Phase 4 Morphine Sulfate ER;Oxycodone ER;Oxymorphone ER
46 Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Enrolling by invitation NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
47 Liposomal Bupivacaine in Ambulatory Hand Surgery Enrolling by invitation NCT02933814 Phase 4 Liposomal Bupivicaine
48 XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept Not yet recruiting NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
49 Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption Not yet recruiting NCT03534102 Phase 4 Improved Opioid-Tapering Instructions
50 Gabapentin Regimens and Their Effects on Opioid Consumption Not yet recruiting NCT03334903 Phase 4 Gabapentin

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

41
Testes, Brain, Liver, Bone, Eye, Fetal Brain, Pituitary

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 997)
# Title Authors Year
1
Opiate Dependence or Addiction?: A Review of the Centers for Disease Control and Prevention Guidelines for Management of Chronic Pain. ( 29505462 )
2018
2
Predicting health-related quality of life (EQ-5D-5A L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP. ( 29843726 )
2018
3
Factors predicting opioid dependence in patients undergoing surgery for degenerative spondylolisthesis: analysis from the MarketScan databases. ( 29914294 )
2018
4
The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. ( 30157924 )
2018
5
Opioid Dependence and Health Care Utilization Following Decompression and Fusion in Patients with Adult Degenerative Scoliosis. ( 30015717 )
2018
6
Health care utilization and overall costs based on opioid dependence in patients undergoing surgery for degenerative spondylolisthesis. ( 29712535 )
2018
7
Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study. ( 29807218 )
2018
8
Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS. ( 30391868 )
2018
9
Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. ( 29333880 )
2018
10
Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients. ( 29346444 )
2018
11
Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness. ( 29415846 )
2018
12
Genome-wide Association Study Identifies a Regulatory Variant of RGMA Associated With Opioid Dependence in European Americans. ( 29478698 )
2018
13
Opioid Omission Is Not Opioid Sparing. Response to "Surgery-Induced Opioid Dependence: Adding Fuel to the Fire?" ( 29481439 )
2018
14
Mindfulness-based interventions modulate structural network strength in patients with opioid dependence. ( 29494858 )
2018
15
Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence. ( 29560596 )
2018
16
Management of chronic pain and opioid dependence with buprenorphine/naloxone. ( 29573109 )
2018
17
Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. ( 29793599 )
2018
18
Opioid Dependence and Prolonged Length of Stay in Lumbar Fusion: A Retrospective Study Utilizing the National Inpatient Sample 2003-2014. ( 29794587 )
2018
19
Correction to: Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence. ( 29796833 )
2018
20
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. ( 29806872 )
2018
21
Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin. ( 29857327 )
2018
22
Serum BDNF levels in patients with opioid dependence during the early withdrawal period: A case control study. ( 29859931 )
2018
23
Authors' Response to Silverman and Colleagues' Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence". ( 29956219 )
2018
24
Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence". ( 29956220 )
2018
25
Non-medical Cannabis Self-Exposure as a Dimensional Predictor of Opioid Dependence Diagnosis: A Propensity Score Matched Analysis. ( 29997535 )
2018
26
Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. ( 30107320 )
2018
27
Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence. ( 30117074 )
2018
28
Dynamic associations between opioid use and anhedonia: A longitudinal study in opioid dependence. ( 30130143 )
2018
29
Supervised Injectable Opioid Treatment for the Management of Opioid Dependence. ( 30132259 )
2018
30
Effect of opioid dependence or abuse on opioid utilization after shoulder arthroplasty. ( 30148070 )
2018
31
Which Criteria to Use to Identify Metabolic Syndrome among Patients with Addictive Disorders?: Observations among Patients with Alcohol and Opioid Dependence Syndrome. ( 30148108 )
2018
32
Improving outcomes in the treatment of opioid dependence (IOTOD): reflections on the impact of a medical education initiative on healthcare professionals' attitudes and clinical practice. ( 30202635 )
2018
33
Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. ( 30280448 )
2018
34
Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence. ( 30300292 )
2018
35
Chronic co-administration of nalbuphine attenuates the development of opioid dependence. ( 30312633 )
2018
36
Substance misuse in patients who have comorbid chronic pain in a clinical population receiving methadone maintenance therapy for the treatment of opioid dependence. ( 30368067 )
2018
37
Can Tramadol be Used for Maintenance Treatment of Opioid Dependence? ( 30395757 )
2018
38
A computational strategy for finding novel targets and therapeutic compounds for opioid dependence. ( 30403753 )
2018
39
ANCO-GeneDB: annotations and comprehensive analysis of candidate genes for alcohol, nicotine, cocaine and opioid dependence. ( 30403795 )
2018
40
Interrelationship of Opioid Dependence, Impaired Impulse Control, and Depressive Symptoms: An Open-Label Cross-Sectional Study of Patients in Maintenance Therapy. ( 30453290 )
2018
41
Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial. ( 30460781 )
2018
42
Transcranial direct current stimulation to prevent and treat surgery-induced opioid dependence: a systematic review. ( 30516441 )
2018
43
A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. ( 27958381 )
2018
44
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. ( 28402682 )
2018
45
Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. ( 28576389 )
2018
46
Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence. ( 28593748 )
2018
47
An analysis of genetic association in opioid dependence susceptibility. ( 28656735 )
2018
48
Perceived stigma and social support in treatment for pharmaceutical opioid dependence. ( 28884866 )
2018
49
Compulsivity in opioid dependence. ( 28918267 )
2018
50
Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. ( 28930612 )
2018

Variations for Opiate Dependence

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CREB1 DRD2 DRD3 IGF1 NGF OPRD1
2
Show member pathways
13.32 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
3
Show member pathways
12.85 CREB1 NGF OPRM1 PDYN POMC
4
Show member pathways
12.75 CREB1 DRD2 DRD3 OPRM1 TH VEGFA
5
Show member pathways
12.51 DRD2 IGF1 NGF VEGFA
6
Show member pathways
12.3 CREB1 OPRM1 PDYN POMC
7 12.17 CREB1 NGF OPRM1 POMC TH TPH1
9
Show member pathways
11.74 CREB1 DRD2 PDYN TH
10 11.68 OPRD1 OPRM1 POMC VEGFA
11
Show member pathways
11.66 DRD2 DRD3 TH
12 11.46 IGF1 NGF TH VEGFA
13 11.31 CREB1 NGF SLC6A4 TH TPH1 VEGFA
14 11.26 DRD2 IGF1 NGF
15
Show member pathways
10.9 TH TPH1
16 10.89 DRD2 DRD3
17 10.83 CREB1 TH

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.93 DRD2 DRD3 OPRD1 OPRK1 OPRM1 SLC6A4
2 axon GO:0030424 9.8 CREB1 DRD2 NGF OPRM1 TH
3 dendrite GO:0030425 9.73 DRD2 NGF OPRK1 OPRM1 PDYN TH
4 perikaryon GO:0043204 9.62 DRD2 OPRK1 OPRM1 TH
5 axon terminus GO:0043679 9.46 DRD2 OPRD1 OPRK1 PDYN
6 dopaminergic synapse GO:0098691 9.43 DRD2 DRD3
7 spine apparatus GO:0097444 9.37 OPRD1 OPRM1
8 integral component of postsynaptic membrane GO:0099055 9.26 DRD2 OPRK1 OPRM1 SLC6A4
9 integral component of presynaptic membrane GO:0099056 9.02 DRD2 OPRD1 OPRK1 OPRM1 SLC6A4

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.97 OPRD1 OPRM1 POMC VEGFA
2 negative regulation of gene expression GO:0010629 9.95 CREB1 IGF1 OPRD1 VEGFA
3 response to drug GO:0042493 9.92 CREB1 DRD2 DRD3 SLC6A4 TH
4 circadian rhythm GO:0007623 9.85 CREB1 SLC6A4 TPH1
5 response to hypoxia GO:0001666 9.83 CREB1 DRD2 SLC6A4 TH VEGFA
6 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.82 OPRD1 OPRK1 OPRM1
7 cellular response to growth factor stimulus GO:0071363 9.81 CREB1 OPRD1 TH
8 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.81 OPRD1 OPRK1 OPRM1
9 social behavior GO:0035176 9.8 DRD3 SLC6A4 TH
10 visual learning GO:0008542 9.78 CREB1 DRD2 DRD3
11 response to nicotine GO:0035094 9.76 CREB1 DRD2 TH
12 memory GO:0007613 9.76 CREB1 NGF SLC6A4 TH
13 arachidonic acid secretion GO:0050482 9.72 DRD2 DRD3
14 response to immobilization stress GO:0035902 9.72 TH TPH1
15 positive regulation of receptor internalization GO:0002092 9.72 DRD2 VEGFA
16 positive regulation of neuroblast proliferation GO:0002052 9.72 DRD2 VEGFA
17 response to amphetamine GO:0001975 9.72 DRD2 DRD3 TH
18 response to ethanol GO:0045471 9.72 DRD2 DRD3 OPRK1 OPRM1 TH
19 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.71 DRD2 DRD3
20 positive regulation of Ras protein signal transduction GO:0046579 9.71 IGF1 NGF
21 dopamine receptor signaling pathway GO:0007212 9.71 DRD2 DRD3
22 eye photoreceptor cell development GO:0042462 9.71 TH VEGFA
23 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD3
24 regulation of sensory perception of pain GO:0051930 9.71 OPRD1 OPRK1 OPRM1
25 positive regulation of long-term synaptic potentiation GO:1900273 9.7 CREB1 DRD2
26 mammary gland alveolus development GO:0060749 9.7 TPH1 VEGFA
27 positive regulation of CREB transcription factor activity GO:0032793 9.7 OPRD1 VEGFA
28 estrous cycle GO:0044849 9.7 OPRK1 OPRM1
29 response to growth factor GO:0070848 9.69 OPRM1 TH
30 dopamine metabolic process GO:0042417 9.69 DRD2 DRD3
31 prepulse inhibition GO:0060134 9.69 DRD2 DRD3
32 neurotransmitter biosynthetic process GO:0042136 9.68 SLC6A4 TH
33 positive regulation of renal sodium excretion GO:0035815 9.68 DRD2 DRD3
34 G protein-coupled receptor internalization GO:0002031 9.68 DRD2 DRD3
35 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.67 DRD3 OPRM1
36 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD3 OPRK1
37 response to cocaine GO:0042220 9.67 DRD2 DRD3 OPRK1 OPRM1
38 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.66 DRD2 DRD3
39 sensory perception GO:0007600 9.66 OPRK1 OPRM1
40 aromatic amino acid family metabolic process GO:0009072 9.65 TH TPH1
41 behavioral response to ethanol GO:0048149 9.65 DRD2 OPRM1
42 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 DRD3 TH
43 neuropeptide signaling pathway GO:0007218 9.65 OPRD1 OPRK1 OPRM1 PDYN POMC
44 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.62 DRD2 DRD3
45 negative regulation of dopamine receptor signaling pathway GO:0060160 9.6 DRD2 DRD3
46 acid secretion GO:0046717 9.58 DRD2 DRD3
47 opioid receptor signaling pathway GO:0038003 9.58 OPRD1 OPRK1 OPRM1
48 regulation of locomotion involved in locomotory behavior GO:0090325 9.57 DRD2 DRD3
49 response to histamine GO:0034776 9.56 DRD2 DRD3
50 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.51 OPRK1 OPRM1

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.85 DRD2 DRD3 OPRD1 OPRK1 OPRM1
2 adrenergic receptor activity GO:0004935 9.43 DRD2 DRD3
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD2 DRD3
4 receptor serine/threonine kinase binding GO:0033612 9.37 OPRD1 OPRK1
5 neuropeptide binding GO:0042923 9.33 OPRD1 OPRK1 OPRM1
6 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD2 DRD3
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.26 TH TPH1
8 dopamine binding GO:0035240 9.13 DRD2 DRD3 TH
9 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Opiate Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....